[go: up one dir, main page]

EP1066311A4 - Compositions et methodes d'identification de cellules de tumeur du poumon - Google Patents

Compositions et methodes d'identification de cellules de tumeur du poumon

Info

Publication number
EP1066311A4
EP1066311A4 EP99914285A EP99914285A EP1066311A4 EP 1066311 A4 EP1066311 A4 EP 1066311A4 EP 99914285 A EP99914285 A EP 99914285A EP 99914285 A EP99914285 A EP 99914285A EP 1066311 A4 EP1066311 A4 EP 1066311A4
Authority
EP
European Patent Office
Prior art keywords
compositions
identification
methods
tumor cells
lung tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99914285A
Other languages
German (de)
English (en)
Other versions
EP1066311A1 (fr
Inventor
Gary A Beaudry
Stephen L Madden
Arthur H Bertelsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to EP06026756A priority Critical patent/EP1790717A3/fr
Priority to EP03002096A priority patent/EP1310556A3/fr
Publication of EP1066311A1 publication Critical patent/EP1066311A1/fr
Publication of EP1066311A4 publication Critical patent/EP1066311A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP99914285A 1998-03-31 1999-03-30 Compositions et methodes d'identification de cellules de tumeur du poumon Withdrawn EP1066311A4 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06026756A EP1790717A3 (fr) 1998-03-31 1999-03-30 Compositions et procédés d'identification de cellules cancéreuses du poumon
EP03002096A EP1310556A3 (fr) 1998-03-31 1999-03-30 Compositions et méthodes d'identification de cellules de tumeur du poumon

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8003798P 1998-03-31 1998-03-31
US80037P 1998-03-31
PCT/US1999/006938 WO1999050278A1 (fr) 1998-03-31 1999-03-30 Compositions et methodes d'identification de cellules de tumeur du poumon

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP03002096A Division EP1310556A3 (fr) 1998-03-31 1999-03-30 Compositions et méthodes d'identification de cellules de tumeur du poumon

Publications (2)

Publication Number Publication Date
EP1066311A1 EP1066311A1 (fr) 2001-01-10
EP1066311A4 true EP1066311A4 (fr) 2002-04-10

Family

ID=22154860

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99914285A Withdrawn EP1066311A4 (fr) 1998-03-31 1999-03-30 Compositions et methodes d'identification de cellules de tumeur du poumon

Country Status (5)

Country Link
EP (1) EP1066311A4 (fr)
JP (1) JP2002509707A (fr)
AU (1) AU757478C (fr)
CA (1) CA2323833A1 (fr)
WO (1) WO1999050278A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3217599A (en) * 1998-03-31 1999-10-18 Genzyme Corporation Methods for the diagnosis and treatment of lung cancer
AU2001251084A1 (en) * 2000-03-29 2001-10-08 Diadexus, Inc. Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
EP1358349A2 (fr) * 2000-06-05 2003-11-05 Avalon Pharmaceuticals Determination de gene du cancer et recherche therapeutique utilisant des ensembles de genes signature
US7332590B2 (en) 2001-08-16 2008-02-19 The United States Of America As Represented By The Department Of Health And Human Services Molecular characteristics of non-small cell lung cancer
AU2002353972A1 (en) * 2001-11-02 2003-05-19 Pfizer Products Inc. Lung cancer therapeutics and diagnostics
WO2006056080A1 (fr) * 2004-11-29 2006-06-01 Diagnocure Inc. Gene gpx2, cible specifique et sensible pour le diagnostic, le pronostic et/ou la theranose concernant le cancer du poumon

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042211A1 (fr) * 1996-05-06 1997-11-13 Chiron Corporation GENE MAMMALIEN Scm A EFFET SUPPRESSEUR DE TUMEUR

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3163090B2 (ja) * 1988-01-21 2001-05-08 マサチューセッツ アイ アンド イヤー インファーマリー 網膜芽腫診断剤
JPH03503843A (ja) * 1988-04-15 1991-08-29 バイオジェン インコーポレイテッド ホスホリパーゼａ２の精製方法およびホスホリパーゼａ２様ポリペプチドの製造方法
WO1990005745A1 (fr) * 1988-11-18 1990-05-31 The General Hospital Corporation Proteine de liaison stimulatrice de transcription reagissant au monophosphate d'adenosine cyclique
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042211A1 (fr) * 1996-05-06 1997-11-13 Chiron Corporation GENE MAMMALIEN Scm A EFFET SUPPRESSEUR DE TUMEUR

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BACHER N ET AL.: "Isolation and characterzation of PKC-L, a new member of the protein kinase C-related gene family specifically expressed in lung, skin and heart.", MOLECULAR CELL BIOLOGY, vol. 11, no. 1, January 1991 (1991-01-01), XP001032543 *
BACHER N. ET AL: "Isolation and characterization of PKC-L, a new member of the protein kinase C-related gene family specifically expressed in lung, skin, and heart", MOL CELL BIOL, vol. 11, no. 1, 1991, pages 126 - 133, XP001032543 *
BIRRER MJ AND BROWN PH: "Application of molecular genetics to the early diagnosis and screening of lung cancer", CANCER RESEARCH., vol. 52, no. suppl, 1 May 1992 (1992-05-01), AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, pages 2658s - 2664s, XP002180205, ISSN: 0008-5472 *
DATABASE GENBANK E.B.I. HINXTON U.K.; 17 February 1997 (1997-02-17), ZSCHUNKE F: "Serine Esterase" *
DATABASE GENBANK E.B.I. Hinxton U.K.; 17 February 1997 (1997-02-17), ZSCHUNKE F: "Serine Esterase", XP002179576 *
DATABASE GENBANK E.B.I. Hinxton U.K.; 18 May 1994 (1994-05-18), HALLEWELL RA: "Mouse Manganese Superoxide Dismutase", XP002179578 *
DATABASE GENBANK E.B.I. HINXTON U.K.; 18 May 1994 (1994-05-18), HALLEWELL RA: "Murine Superoxide Dismutase" *
DATABASE GENBANK E.B.I. HINXTON U.K.; 27 April 1993 (1993-04-27), LONG RM: "Liver Carboxylesterase" *
DATABASE GENBANK E.B.I. HINXTON U.K.; 7 January 1995 (1995-01-07), BACHER N: "Protein Kinase C-L" *
DATABASE GENBANK E.B.I. Hinxton, U.K.; 27 April 1993 (1993-04-27), LONG RM: "Human Liver Carboxylesterase isoezyme", XP002179577 *
SALGIA R AND SKARIN AT: "Molecular abnormalities in lung cancer", JOURNAL OF CLINICAL ONCOLOGY, vol. 16, no. 3, March 1998 (1998-03-01), PHILADELPHIA, PA, US, pages 1207 - 1217, XP001030483 *
SALGIA R. AND SKARIN A.T.: "Molecular abnormalities in lung cancer", JOURNAL OF CLINICAL ONCOLOGY, vol. 16, no. 3, March 1998 (1998-03-01), pages 1207 - 1217, XP001030483 *
See also references of WO9950278A1 *
VAN ZANDWIJK N AND VAN 'T VEER L: "The role of prognostic factors and oncogenes in the detection and management of Non-Small-Cell Lung Cancer", ONCOLOGY., vol. Supplement 2, January 1998 (1998-01-01), S. KARGER AG, BASEL., CH, pages 55 - 59, XP001031838, ISSN: 0030-2414 *
VAN ZANDWIJK N. AND VAN 'T VEER L.: "The role of prognostic factors and oncogenes in the diagnosis and management of Non-Small-Cell Lung Cancer.", ONCOLOGY, vol. SUPPL 2, January 1998 (1998-01-01), pages 55 - 59, XP001031838 *

Also Published As

Publication number Publication date
AU757478B2 (en) 2003-02-20
EP1066311A1 (fr) 2001-01-10
AU3216899A (en) 1999-10-18
JP2002509707A (ja) 2002-04-02
AU757478C (en) 2004-03-25
CA2323833A1 (fr) 1999-10-07
WO1999050278A1 (fr) 1999-10-07

Similar Documents

Publication Publication Date Title
AU2212299A (en) Compositions and methods for the treatment of tumor
AU3905399A (en) Methods and compositions for transgene identification
IL139247A0 (en) Hematopoietic stimulation
HUP0100765A3 (en) Composition for the treatment of halitosis
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AP2000002010A0 (en) Novel pharmaceutical compositions for treating and saving and the methods for the preparation thereof
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
GB2361996B (en) Multiple marker characterization of single cells
EP1056456A4 (fr) Compositions et procedes d'utilisation du r-lansoprazole
EP1056457A4 (fr) Compositions de s-lansoprazole et procedes d'utilisation
IL145520A0 (en) Flame-retarding composition and process for the preparation thereof
SG53062A1 (en) Manufacture of bisphenol-a
ZA200006300B (en) Composition comprising tumor cells and extracts and method of using thereof.
ZA954984B (en) Compositions and methods for the treatment of tumors
IL141426A0 (en) Compositions and methods for the treatment of tumor
IL143212A0 (en) Compositions and methods for the treatment of tumor
EP1073333A4 (fr) Compositions a base de s-rabeprazole et procedes
EP1066311A4 (fr) Compositions et methodes d'identification de cellules de tumeur du poumon
HUP0101947A3 (en) Combination for the treatment of tumors
EP1139981A4 (fr) Compositions et procedes d'utilisation associes
GB9824444D0 (en) Micro-Organism identification
EP1073332A4 (fr) Compositions a base de r-rabeprazole et procedes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020225

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020530

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030503